Author

Yesid Alvarado‐Valero

Observed names: Y. Alvarado-Valero, Yesid Alvarado-Valero

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

OpenAlex ID: A5089764596

Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial

2025 · Sonja Loges, Michael Heuser, et al. · Nature Communications · 19

Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

2020 · Koji Sasaki, Hagop Kantarjian, et al. · American Journal of Hematology · 15

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia

2024 · Jayastu Senapati, Elias Jabbour, et al. · Blood · 9

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

2023 · Sonja Loges, Michael Heuser, et al. · Blood · 5

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

2023 · Wei-Ying Jen, Courtney D. DiNardo, et al. · Blood · 4

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

2024 · Yesid Alvarado-Valero, Rachel J. Cook, et al. · Blood · 2

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

2023 · Niklas Beumer, Jonas S. Waizenegger, et al. · Blood · 2

P548: Bemcentinib Combined With Low-dose Cytarabine Is Efficacious and Well Tolerated in Relapsed Aml Patients Unfit for Intensive Chemotherapy. Updates From the Ongoing Phase Ii Trial (nct02488408)

2022 · S. Loges, M. Heuser, et al. · HemaSphere · 1

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

2024 · Danielle Hammond, Koji Sasaki, et al. · Blood

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

2024 · Jennifer Marvin-Peek, Hagop M. Kantarjian, et al. · Blood

Works count: 10

Citation count: 57

H-index: 4

I10-index: 2